Clinical trial
Rosiglitazone-Induced Weight Gain
NCT00225225 · Stanford University, Other · Terminated
Key facts
| NCT number | NCT00225225 |
|---|---|
| Title | Rosiglitazone-Induced Weight Gain |
| Official title | Rosiglitazone-Induced Weight Gain |
| Lead sponsor | Stanford University, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Behavioral, Drug |
| Interventions | Rosiglitazone, dietary recommendation for weight maintenance |
| Enrollment | 45 |
| Start date | Oct 1, 2002 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Sep 23, 2005 |
| Last update posted | Oct 20, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: